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ABSTRACT 
Objective: The objective of the present work is to develop a bi-layer tablet consisting of an Immediate Pulse Release [IPR] layer and a sustained 
release [SR] layer that can produce a distinct biphasic release having two different drug release rates. The IPR layer is intended to release a fraction 
of the dose rapidly at a faster rate and the SR layer is meant for slow release of the remaining dose at a slower rate for a desired period of time. 
Methods: The quantitative determination was carried out by UV spectrophotometer. Solid dispersion was prepared by melt method. IPR layer was 
prepared by direct compression method, SR layer was prepared by wet granulation method. In-vitro drug release study from tablets was carried out 
in USP II tablet dissolution rate test apparatus. FTIR, DSC, XRD studies were performed. 
Results: 89% of the incorporated drug was released within 30 min in acid solution of pH 1.2 from the IPR tablet prepared with the highest amount 
of gelucire due to solid state transformation of the drug. The SR layer (SR8) comprising of SAL, CG and CMC produced prolonged drug release (70% 
in 10 h). The optimized IPR3 layer and SR layers were compressed to form bi-layer tablets from which 23-37% drug was released immediately in 30 
min, and the remaining drug was released slowly for 7 to 10 h depending upon the compositions of the tablets. 
Conclusion: This study revealed that bi-phasic release of GPZ consisting of an initial quick release and subsequent slow release could be achieved 
by formulating bi-layer tablets using the existing tablet technology, and such formulation may be able to control hyperglycaemia effectively for a 
longer period of time 
Keywords: IPR, SR, Glipizide, Solid Dispersion, Normoglycaemia Bilayer Tablets, Biphasic release. 
 
INTRODUCTION 
During the last several years’ development of modified release drug 
delivery system (DDS) remains on the thrust areas of research in 
pharmaceutical product development. Oral SRDDS have been 
developed to provide release of a drug at a constant rate for better 
compliance and therapy to the patients who need long term and 
continuous therapy. Oral site specific DDS, also known as slow/quick 
DDS, have been developed to minimize the drug release in upper 
gastrointestinal tract and to provide rapid release in the colon for 
local therapeutic effect [1]. However, for the treatment of many 
diseases, an ideal dosage regimen require an immediate attainment 
of therapeutic drug concentration at the site of action, and then to 
maintain the level for the desired period of time/treatment. This 
type of dosage forms is necessary to arrest the symptoms and to 
achieve maximum relief immediately, and then to provide sustained 
drug release for avoiding repeated administration. SR dosage forms 
generally lead to delayed attainment of therapeutic plasma drug 
concentration and are unable to provide a rapid disposition of the 
dose immediately after administration [2]. Such drug delivery 
systems can be modified by applying barrier layers to one or both 
sides of the tablets to restrict the surface area exposed to a fluid [3, 
4]. However, many of the multilayer systems provide a constant 
release rate of drugs from tablets instead of a biphasic release [5]. 
Thus, with a view to achieve an immediate relief of symptoms 
associated with a disease and then to maintain the relieved 
condition for a longer period of time, the concept of biphasic DDS 
have emerged. This delivery system is capable of releasing a drug at 
two different rates, i.e. in a quick/slow manner depending on the 
need of the patients. 
Diabetes mellitus is a chronic disease which is characterized by high 
blood glucose level due to either insufficient secretion of insulin 
from the pancreas or ineffective utilization of glucose by the body [6, 
7]. Sustained hyperglycaemia may lead to several complications and 
organ failure [8]. The rationality in diabetes treatment is to achieve 
normoglycaemia/euglycaemia quickly, and then to maintain the 
normoglycaemic condition over a desired period of time [9]. For 
such therapy, a DDS should be designed in such a way that a 
precalculated dose of the drug is released rapidly to produce 
normoglycaemia, and the remaining dose is released slowly sufficient 
to maintain the normoglycaemia over a desired period of time. 
Formulation of tablets using the existing and well established tablet 
technology appears to be very suitable for achieving biphasic drug 
release. In recent years, various researchers have reported the 
development of bi-layer tablets of either single drug [5, 10] or a 
combination of drugs within the same therapeutic category [11, 12] 
for quick/slow type of biphasic release of drugs. Biphasic release of 
drugs was also achieved through formulation of gastro retentive 
floating multiple tablets [13], musoadhesive matrix tablets [14]. 
Most of the reports deal with the compression of an IPR layer over a 
SR layer to form a bilayer tablet. The principle involved in achieving 
quick release is rapid disintegration of IPR layer using super 
disintegrants. However, for a poorly water soluble drug, IPR is 
dissolution rate limited. Solid dispersion is a technology which 
induces solid state transformation/molecular dispersion of drugs 
enhancing the rate of dissolution considerably. 
In the present investigation, GPZ, an antidiabetic drug, has been 
selected as a model drug for developing bi-layer tablets. The drug is 
characterized by a short biological half life of 3.4±0.7 h [15] 
requiring administration in a dose of 2.5 to 10 mg in 2-3 divided 
doses [16]. Moreover, it falls under class II category of 
Biopharmaceutical Classification System exhibiting poor aqueous 
solubility and thus making absorption as dissolution rate limited. 
The objective of the present work is to develop a bi-layer tablet 
consisting of an IPR layer and a SR layer that can produce a distinct 
biphasic release having two different drug release rates. The IPR 
layer is intended to release a fraction of the dose rapidly at a faster 
rate and the SR layer is meant for slow release of the remaining dose 
at a slower rate for a desired period of time. To achieve instant 
release of a fraction of the dose, the solubility and dissolution rate of 
GPZ was increased by solid dispersion technique, using gelucire as a 
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water soluble carrier. Gelucire has been reported to be non toxic and 
is suitable for use in tabletting, capsule filling [17] and have high 
solubilizing property [18, 19]. The resulting solid dispersion was 
converted into IPR layer of the bi-layer tablet. The release rate 
retarding SR layer was formulated using sodium alginate (SAL) with 
or without carboxymethyl cellulose (CMC) and CG. Initially the IPR 
and SR layers were optimized separately, and finally the Bi-layer 
tablet was evaluated for distinct biphasic release. 
MATERIALS AND METHODS 
Glipizide (GPZ), Indian Pharmacopoeia, was a generous gift from 
Stadmed Pvt Ltd, Kolkata India. Gelucire 44/14 and Microcrystalline 
Cellulose (MCC) were donated respectively by Gattefosse, Saint-
Priest Cedex-France, and Dr Reddy’s Lab, Hyderabad, India. Lactose 
Monohydrate and Calcium Gluconate (CG) from Himedia, Mumbai, 
India, SAL, SD Fine chem. Pvt Ltd Mumbai, India, CMC, Loba Chemie, 
Mumbai, India, Magnesium Stearate and all other ingredients were 
obtained commercially and used as received. Double distilled water 
was used throughout the experiment. 
Preparation of solid dispersion 
Solid dispersion of GPZ and gelucire was prepared by fusion method 
using three different ratios of GPZ/Gelucire (weight ratios of 1:1, 
1:3, 1:5). Accurately weighed amount of gelucire was taken in an 
aluminium pan and melted on a water bath at 60 °C with constant 
stirring. Required amount of GPZ was added into the melted carrier 
with stirring to achieve a homogeneous mass which was then 
allowed to cool to room temperature. Lactose was added to the mass 
during cooling. The resulting solid dispersion was sieved through # 
85 mesh BS screen and stored in desiccator until use.  
Solubility study  
Excess drug was added in 10 ml double distilled water contained in 
50 ml stopper conical flask and was shaken for 48 h on a mechanical 
shaker at 37 °C. The mixture was filtered through whatman filter 
paper no 1, and aliquot, following suitable dilution, was analyzed at 
276 nm using a spectrophotometer (Multiscan Go, Thermoscientific, 
USA). The solubility of the drug was determined from calibration 
curve. Similarly, the solubility of GPZ was determined in acid 
solution (0.1 (N) HCl, pH 1.2) and phosphate buffer (PB) solution 
(pH 6.8). All experiments were done in triplicate.  
Phase solubility study  
For phase solubility study, required amount of gelucire (0, 2, 4, 6, 8, 
10 and 12 %w/v) was added in 10 ml acid solution (pH 1.2) in a 
stopper 50 ml conical flask. Excess powdered drug was added in 
each of the conical flasks and shaken for 48 h on a mechanical 
shaker at 37 °C. The mixture was filtered, and an aliquot, following 
suitable dilution, was analyzed at 276 nm spectrophotometrically to 
determine the solubilities. The experiment was repeated in a similar 
fashion in PB solution (pH 6.8). The solubility of GPZ in presence of 
different amount of gelucire has been shown in [table 1]. 
  
Table 1: Phase solubility and G0
Conc of Gelucire 
44/14 (%w/v) 
tr of glipizide at different concentration of gelucire 44/14 
Solubility of GPZ and its associated gibbs free energy 
in acid buffer ph 1.2 
Solubility of GPZ and its associated Gibbs free energy in 
phosphate buffer ph 6.8 
Solubility of GPZ 
(µg/ml)±SD(n=3) 
-g0 Solubility of GPZ (µg/ml)±SD(n=3) tr (J/K/mol) -g0tr (J/K/mol) 
0 1.383333±0.11 0 5.035±0.017 0 
2 4.05±0.16 -2770.47 35.02333±1.83 -5002.16 
4 8.1±1.63 -4558.14 45.32333±1.46 -5667.06 
6 13.53333±0.96 -5881.94 51.61333±1.52 -6002.23 
8 18.21333±0.28 -6647.92 57.09333±1.85 -6262.48 
10 22.16667±0.23 -7154.54 62.53333±0.69 -6497.2 
12 21.52333±2.17 -7078.58 58.94333±0.30 -6344.72 
14 18.76667±0.43 -6725.1 37.59±1.02 -5184.56 
16 17.10333±0.24 -6485.75 26.85±1.61 -4316.78 
 
Table 2: Compositions of IPR tablets 
Formulation Code GPZ(mg) Gelucire 44/14 
(mg) 
GPZ: Gelucire Lactose (mg) Avicel PH 102(mg) Mag St(mg) Total(mg) 
Control 1.5 -- -- 53.55 124.95 2 182 
IPR1 1.5  1.5 1:1 53.1 123.9 2 182 
IPR2 1.5 4.5 1:3 52.2 121.8 2 182 
IPR3 1.5 7.5 1:5 51.3 119.7 2 182 
 
Table 3: Compositions of SR tablets 
Formulation Code GPZ(mg) SAL (mg) HVCMC(mg) CG(mg) Polymer: CG Mag St Total (mg) 
SR1 3.5 100 0 100 1:1 2 205.5 
SR2 3.5 100 0 130 1:1.3 2 235.5 
SR3 3.5 100 0 150 1:1.5 2 255.5 
SR4 3.5 100 0 180 1:1.8 2 285.5 
SR5 3.5 86.6 0 129.9 1:1.5 2 222 
SR6 3.5 60.62 25.98 129.9 1:1.5 2 222 
SR7 3.5 43.3 43.3 129.9 1:1.5 2 222 
SR8 3.5 25.98 60.62 129.9 1:1.5 2 222 
 
Preparation of IPR tablet  
IPR tablets, the compositions of which are shown in [table 2], were 
prepared by direct compression method. Solid dispersion 
(equivalent to 1.5 mg of GPZ), MCC and Mg-Stearate were blended 
manually for 10 min and compressed into tablets using 8.7 mm flat 
face punch in a tablet machine (RIMEK, Karnavati Engineering Ltd., 
Gujarat, India). The crushing strength and weight of the tablets were 
kept constant respectively at 2 kg and 182 mg. Control tablets 
without containing solid dispersion were prepared in a similar way. 
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Preparation of SR tablet 
SR tablets, the compositions of which are shown in [table 3], were 
prepared by wet granulation method. GPZ, SAL, CMC and CG were 
blended, moistened with required amount of water, and granulated 
using #18 mesh BS screens. The granules were dried at 60 °C for 
sufficient time till the moisture content in the granules reduced to 
about 2% w/w. The dried granules were passed through #22 mesh 
BS screen, mixed with Mg-Stearate and compressed into tablet using 
8.7 mm flat face punch. The crushing strength of the tablets was kept 
constant at 4 kg. 
 
Preparation of Bi-Layer tablets 
For the preparation of bi-layer tablet, initially the granules of SR 
layer were compressed in the tablet machine using 8.7 mm flat face 
punch. Upon this layer, the granules of the IPR layer were placed 
manually and further compressed. Bi-layer tablets, the compositions 
of which are shown in [table 4] were designated as BL1 to BL4. Total 
amount (5 mg) of the drug in bi-layer tablet was divided into two 
fractions (1.5 mg in IPR layer and 3.5 mg in SR layer) following the 
report published elsewhere [20]. The crushing strength of the 
tablets was kept constant at 4 kg. 
Table 4: Compositions of bi-layer tablets 
Formulation code IPR code SR code 
BL1 IPR3 SR5 
BL2 IPR3 SR6 
BL3 IPR3 SR7 
BL4 IPR3 SR8 
 
Evaluation of IPR, SR and BL tablets  
Weight variation test  
Twenty tablets were weighed individually in an electronic pan 
balance (XB 600 M-C, Precisa, Switzerland). The weight of each 
tablet was compared with the average weight of the tablets. 
Crushing strength of tablets  
Crushing strength of the tablets was determined using Monsanto 
type Tablet Hardness Tester (Campbell Electronics, Mumbai, India) 
and average value of 10 determinations was reported. 
Thickness of tablets  
The thickness of each tablet was measured with a Digimatic Caliper 
(CD-6"CS, Mitutoyo Corporation, Japan) and average of 10 
determinations was calculated. 
Friability test  
Ten tablets were weighed and placed in the plastic drum of a 
Friabilator (EF2, Electro Lab, Mumbai, India). After 100 revolutions, 
the tablets were dedusted with a soft brass and reweighed. The 
percentage of weight loss was calculated. 
Disintegration test of IPR tablets 
In-vitro disintegration study of IPR tablets was carried out in USP II 
tablet disintegration test apparatus (Electrolab tablet disintegration 
tester (USP) ED-2L) at a frequency of 28-32 cycles per minute. One 
tablet was placed in 1000 ml acid solution of pH 1.2 maintained at 
37±2 °C. The time (min) required for complete disintegration (when 
no residue of the tablet remains on the screen of the basket or, if any 
residue remains, it consists of fragments of disintegrated parts of 
tablets) of the tablets were noted. 
Drug content of the IPR and SR tablets  
One IPR tablet was weighted and powdered in glass mortar. The 
powder was quantitatively transferred into a 250 ml volumetric 
flask with 150 ml phosphate buffer solution of pH 6.8 was added. 
The stoppered flask was shaken for 24 h in a mechanical shaker and 
volume was made up to the mark with the buffer solution. The 
mixture was filtered and an aliquot following suitable dilution was 
analyzed spectrophotometrically at 276 nm for GPZ content.  
The potency of the tablet was determined in the usual manner using 
a calibration curve constructed in buffer solution (pH 6.8). Average 
drug content of 10 tablets was considered as potency of the tablets. 
The reliability of the above method was judged by conducting 
recovery analysis for three consecutive days at three levels of spiked 
drug solution in the presence or absence of the excipients. The 
recovery averaged 98.51±1.14%. The drug content of SR tablets was 
determined in the similar way. 
In-vitro drug dissolution study 
In-vitro drug release study from IPR tablets was carried out in USP II 
tablet dissolution rate test apparatus (model TDP-06P, Electro Lab, 
Mumbai, India) at a paddle speed of 75 rpm. One tablet was placed in 
1000 ml acid solution (pH 1.2) at 37±0.5 °C. At predetermined time 
intervals, aliquots were withdrawn and replenished immediately with 
the same volume of fresh medium maintained at 37 °C. The aliquots 
following suitable dilution were analyzed spectrophotometrically at 
276 nm to calculate the amount of drug released.  
In-vitro drug release study from SR tablets was performed following 
the method described for delayed release tablets in USP30-NF25. 
Initial drug release study was carried out in 750 ml of acid solution 
for 2 h. Thereafter, the pH of the medium was adjusted within 5 min 
to 6.8 by adding 250 ml of 0.2 (M) tribasic sodium phosphate 
solutions and the dissolution study was continued. The amount of 
drug released was determined using the calibration curves drawn 
respectively in acid solution and phosphate buffer solution. Drug 
release from BL tablets was determined in a similar way. 
Drug-excipient and polymer compatibility study 
The compatibility of GPZ with the excipients and polymers used in 
the preparation of IPR and SR tablets was studied through FTIR, 
DSC, XRD studies. 
Fourier transforms infrared (FTIR) analysis 
FTIR spectra of GPZ, physical mixture, and powdered IPR tablet 
were recorded in a FTIR spectrophotometer (Perkin Elmer, RX-1, 
UK). The samples were mixed with KBr and converted into pellets at 
6 ton pressure with a hydraulic press. The spectra were taken in the 
wave number region of 4000-400/cm. The FTIR spectra of physical 
mixture and powdered SR tablets were determined in a similar way. 
Differential scanning calorimetry (DSC) study  
DSC thermograms of GPZ, physical mixture, and powdered IPR tablet 
were obtained using Perkin Elmer (Pyris Diamond TG/DTA, 
Singapore) differential scanning calorimeter which was calibrated 
against indium. Weighed amount of the sample was kept in a 
hermetically sealed aluminum pan and heated at a rate of 10oC/min 
over a temperature range 30-300o
X-Ray powdered diffraction (XRD) study  
C under constant nitrogen flow of 
150 ml/min. Same procedure was followed for the physical mixture 
and powdered SR tablets. 
The qualitative XRD studies of GPZ, physical mixture, and powdered 
IPR tablet were performed using an X-ray diffractometer (ULTIMA-
III, Rigaku, Japan). The samples were scanned from 5 ° to 50 ° 
diffraction angle (2θ) range under the following measurement 
conditions: Source, Ni-filtered Cu-Kα (λ = 1.54) radiation; voltage, 40 
kV; current, 40 mA; scan speed, 1 °/min. The X-ray diffraction 
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patterns of the physical mixture and powdered SR tablet were 
determined in a similar way. 
Data treatment 
Diffusion coefficient of drug  
Diffusion coefficient [Dc, cm2/sec] of GPZ from the tablets were 
determined using [Eq (1)] which was used to calculate the diffusion 
coefficient (Dc) of drug from spherical matrices [21] 
Dc=π (rӨ/6M∞)2………….[1] 
Where r is the equivalent spherical radius of tablet, Ө is the slope of 
linear portion of Mt/M∞ versus t1/2 plot, Mt is the amount of drug 
released at time t (sec), and M∞  is the total amount of drug loaded. 
The equivalent spherical diameter [cm] of the tablets was calculated 
from the relationship:  
d= (6hrc)1/3………………[2] 
Where d, rc, and h represent equivalent spherical diameter, radius, 
and height (cm) of the tablets respectively. 
Drug release mechanism  
To study the kinetics and mechanism of GPZ release from various 
tablets, the In-vitro drug release data were fitted in the following 
equations [table 5]: 
Zero order model [22] 
Mt=M0+K0t………….[3] 
Where Mt is the amount of drug released in time t, M0 is the initial 
amount of drug, and K0 is the zero order release constant. 
First order model [23] 
log M=logM0-K1 (t/2.303)………….[4] 
Where M is the amount of drug released in time t, M0 is the initial 
amount of drug, and K1 is the first order release constant. 
Korsmeyer-Peppas model 
Mt/M∞ = Ktn
Where Mt/M∞ is the fraction of drug released at time t, K is the 
release rate constant and n denotes the diffusional exponent 
indicative of transport mechanism. In case of tablet, n=0.45 indicates 
Fickian diffusion, 0.45<n>0.89 indicates non-Fickian/anamolous 
transport, n=0.89 is for case II transport, and n>0.89 indicates super 
case II transport [24, 25]. Anamolous refers to a combination of both 
erosion and diffusion controlled release and case II refers to erosion 
of polymeric chain. 
……….[5] 
Mean dissolution time (MDT) 
MDT in min was calculated from [Eq 6] [26] using the values of n 





Solid dispersions of GPZ and gelucire prepared in weight ratio of 1:1, 
1:3, and 1:5 were semi solid in nature and were converted into free 
flowing powder by adding lactose as adsorbent. 
The equilibrium solubility of GPZ in water, acid solution (pH 1.2), and 
PB solution (pH 6.8) were found respectively 4.90, 1.48 and 5.04 
µg/ml. The results of phase solubility study are shown in [table 1] 
which indicated a linear increase in solubility with increase in 
concentration of gelucire in both acid solution and PB solution.  
It was further noted that the maximum solubility of the drug was 
attained at 10% w/v concentration of gelucire and beyond which 
the solubility decreased. At 10% w/v concentration of gelucire, 
the solubility of GPZ was enhanced by 15.27 and 12.35 times in 
acid solution and PB solution respectively compared to the 
solubility in water at 37 °C. The Gibb’s free energy was 
calculated from the [Eq. 7] 






 is the ratio of the molar solubility of GPZ after and 
before treatment with carrier. The value of gas constant (R) is 8.314 
J/K/mol and T is temperature in Kelvin (K). It was found that there 
was an increase in the negative values of Gibbs free energy with the 
increase in the concentration of the carrier up to 10% w/v, beyond 
this concentration the negative values of Gibb’s free energy 
decreased.
Table 5: Derived release parameters and release kinetics from IPR, SR, BL tablets 
Formulation code Zero order R First order R2 Korsmeyer-Peppas 2  
n R2 
Control 0.980 0.988 -- -- 
IPR1 0.945 0.982 -- -- 
IPR2 0.879 0.968 -- -- 
IPR3 0.783 0.940 -- -- 
SR1 0.997 0.980 0.811 0.996 
SR2 0.997 0.865 1.006 0.996 
SR3 0.998 0.831 0.987 0.991 
SR4 0.996 0.868 0.980 0.996 
SR5 0.997 0.942 0.821 0.979 
SR6 0.995 0.886 0.951 0.943 
SR7 0.993 0.856 1.14 0.959 
SR8 0.987 0.842 0.986 0.981 
BL1 0.995 0.752 0.236 0.94 
BL2 0.993 0.782 0.262 0.972 
BL3 0.999 0.854 0.356 0.988 
BL4 0.994 0.869 0.379 0.986 
 
IPR, SR and BL tablets complied with specified limits of USP with 
respect to weight variation, drug content, and friability. The variations 
in the thickness of the tablets were within±5% and the crushing 
strength of IPR tablets was kept constant at 2 kg. Control tablets which 
were prepared without gelucire disintegrated within 2 min. However, 
the disintegration time of IPR tablets was found to be protracted from 
3-4 min to 9-10 min with increase in the amount of gelucire. 
Release profiles of GPZ from control and various IPR tablets are 
shown in [fig 1]. The control tablets which was prepared without 
gelucire released 16.53±1.62% and 39.26±2.06% of the loaded drug 
respectively in 30 min and 2 h in acid solution of pH 1.2. The release 
of drug from IPR tablets was higher than that obtained from the 
control tablets. Moreover, increase in the amount of gelucire in the 
IPR tablets increased the drug release considerably. IPR 3 tablet 
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which was prepared with the highest amount of gelucire, released 
89.27±1.95% and 100.09±0.7% of GPZ respectively in 30 min and 2 h. 
 
 
Fig. 1: GPZ release from IPR tablets in acidic solution of pH 1.2 
for 2 h. Filled rhombus control tablet, filled square IPR1, filled 
triangle IPR2, unfilled circle IPR 3. Average±SD,n=3 
 
In-vitro drug release profiles from SR tablets (SR1-SR4) are shown in 
[fig. 2]. SR layer was prepared with various ratios of SAL and CG. 
Increase in amount of CG, which was used as a crosslinking agent, 
decreased the drug release from tablets in the following order 
SR1>SR2>SR3. Further increase in the amount of CG increased the 
drug release as in SR4 tablets. MDT and diffusion coefficient [table 6] 
also followed the same pattern. Increase in the amount of CG 
increased the values of MDT and decreased the values of diffusion 
coefficient. However, in case of SR4, prepared with the highest 
amount of CG, the values of MDT decreased and that of diffusion 
coefficient increased, as shown in table 6. SR tablets, designated as 
SR6, SR7 and SR8, were prepared by substituting SAL with 
increasing amount of CMC, and the drug release profiles of the 
tablets are shown in [fig 3]. The release of GPZ was found to 
decrease with the increase in the amount of CMC. 
 
 
Fig. 2: GPZ release from SR tablets in acidic solution of pH 1.2 
for 2 h followed by phosphate buffer solution (pH 6.8). Filled 
triangle SR1, filled rhombus SR2, filled circle SR3, filled square 
SR4. Average±SD, n=3 
 
Table 6: MDT and diffusion coefficient of drug calculated from the release profile of various SR tablets 
Formulation code MDT (min) 
(mean±SD, n=3) 
Diffusion coefficient (cm2/s)  
(mean±SD, n=3) 
SR1 18.82±0.35 0.019±0.05 
SR2 28.24±2.07 0.012±0.03 
SR3 38.32±0.57 0.008±0.03 
SR4 33.13±0.55 0.011±0.05 
 
 
Fig. 3: GPZ release from SR tablets in acidic solution of pH 1.2 
for 2 h followed by phosphate buffer solution (pH 6.8). Unfilled 
circle SR6, unfilled square SR7, unfilled triangle SR8. 
Average±SD, n=3 
 
BL tablets designated as BL1 to BL4, were prepared with optimum 
formulations of IPR and SR layer. BL tablets immediately released a 
fraction of the loaded drug ranging from 23-37% within first 30 min of 
dissolution study in acid solution of pH 1.2. Thereafter, it slowly released 
the remaining amount of drug. While drug release from BL1 tablet 
extended up to 7 hr, BL4 released 70% of the drug in 10 hr [fig 4]. 
The FTIR spectra of GPZ, physical mixture, and powdered IPR tablets 
are shown in [fig 5]. The peaks at 3251 & 3325/cm for NH 
stretching, 3060/cm for aromatic CH, 2854 to 2941/cm for CH 
stretching, 1649/cm for NH group, 1525 & 1687/cm for C=O group, 
1163 for S=O and 1442 & 686 for CH bending respectively appeared 
in the spectrum of the drug. The peaks were also found in the 
spectra of physical mixture and IPR tablets almost at the same wave 
numbers. The FTIR spectra of the physical mixture and the 
powdered SR tablets also exhibited the characteristics peaks of the 
drug almost at the same wave numbers. 
The DSC thermograms of GPZ, physical mixtures and powdered IPR 
tablets are shown in [fig 6]. The thermogram of GPZ showed a sharp 
melting endotherm at 216 oC. The endotherm was, however, absent 
in the thermograms of physical mixture and IPR tablet. On the other 
hand, melting endotherm at 216o
 
Fig. 4: GPZ release from BL tablets in acidic solution of pH 1.2 
for 2 h followed by phosphate buffer solution (pH 6.8). Unfilled 
triangle BL1, unfilled rhombus BL2, unfilled square BL 3, 
unfilled circle BL4. Average±SD, n=3 
 
C was also observed in the 
thermograms of the physical mixture and powderd SR tablets. 
The XRD of GPZ, physical mixtures and powdered IPR tablets are 
shown in [fig 7]. The diffractogram of GPZ shows sharp peaks at 
7.49, 11.24, 15.67, 17.10, 18.67 and 21.86 ° 2 theta values. The peaks 
were, however, absent in the diffractograms of physical mixture and 
IPR tablet. The diffractograms of physical mixture of the drug and 
excipients used for SR tablet as well as for SR tablet showed the 
characteristics peaks at the respective 2 theta values. 
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Fig. 5: FTIR trace of a) GPZ, b) Solid dispersion of GPZ/Physical mixture of IPR tablets, c) powdered IPR tablets d) powdered SR tablets 
 
 
Fig. 6: DSC thermograms of a) GPZ, b) Gelucire 44/14, c) 
Physical mixture of IPR tablets, d) powdered IPR tablets, e) 
powdered SR tablets 
 
 
Fig. 7: XRD pattern of a) GPZ, b) Gelucire 44/14, c) Physical 




The objective of the present study was to develop bilayer tablets of 
GPZ that can produce euglycaemia rapidly through an IPR of a 
fraction of the dose, and then maintain the euglycaemic level for 
extended period of time through slow release of the remaining 
fraction of the dose. As GPZ exhibits poor aqueous solubility, the 
enhancement of solubility became the first criteria to achieve IPR of 
the drug. Solid dispersion is one of the widely used and established 
methods for enhancing aqueous solubility of poorly water soluble 
drugs [27]. Various water soluble carriers such as polyethylene 
glycols [28], polyvinyl pyrrolidone [29],-β-Cyclodextrin [30] have 
been widely used to develop solid dispersions of poorly water 
soluble drugs like diazepam [31], valdecoxib [28], aceclofenac [32]. 
Gelucire 44/14 (where suffixes 44 and 14 represent its melting 
point and HLB value respectively) has been selected in the present 
study to prepare solid dispersions of GPZ. Gelucire, having low 
melting point, increases aqueous solubility of many poorly water 
soluble drugs considerably [33, 18]. Phase solubility study indicated 
that the solubility of GPZ in both acid solution (pH 1.2) and PB 
solution (pH6.8) increased with increase in the concentration of 
gelucire, reached a limiting value at 10% w/v of gelucire, and then 
decreased [table 1]. The above phenomenon can be explained by 
thermodynamic principles. The solubilization process is 
thermodynamically favored only if the overall Gibb’s free energy of 
the solution is decreased. Associated Gibb’s free energy was 
calculated from the equation 7. Table 1 shows that the negative 
values of Gibb’s free energy increased with the increase in the 
concentration of gelucire, reached a maximum value, and then 
decreased. The increase in the negative values of Gibbs free energy 
with the increase in the concentration of the carrier indicates the 
spontaneity of the solubilization process and that the reaction 
becomes more favorable up to concentration of 10 %w/v. beyond 
that concentration, the negative values of Gibb’s free energy 
decreased, indicating the saturation of solubilization.  
IPR tablets, the compositions of which are shown in table 2, were 
prepared by direct compression method using solid dispersion of 
GPZ with gelucire at three different levels. The wet and sticky solid 
dispersions were converted into free flowing powder for ease of 
compression by adding lactose. Lactose is a common water soluble 
diluent [34], acts as a surface adsorbent [35,36], and enhances the 
dissolution rate of hydrophobic drug by increasing the surface area 
of the solid dispersion [35]. The IPR tablets complied with the 
pharmacopoeial limits of USP with respect to the weight variation, 
content uniformity, friability and thickness. The disintegration time 
of IPR tablets were higher than that of control tablets prepared 
without gelucire. While the disintegration time of control tablets was 
1-2 min, the same increased from 3-4 min to 9-10 min with increase 
in the concentration of gelucire although the hardness of all the 
tablets were kept constant at 2 kg. Increase in disintegration time of 
the IPR tablets with increase in gelucire concentration might be 
related to the soft and waxy nature of the carrier. Such carriers often 
plasticize, melt or soften during compression and fill the pores of the 
tablets leading to increase in the disintegration time [37]. The 
release of GPZ from IPR tablets was higher than that of control 
tablets which were prepared without gelucire. Moreover, the drug 
release increased with increase in concentration of gelucire. While 
39.26±2.05% drug was released from the control tablets in acid 
solution in 2 h, 100.90±0.70% drug was released from IPR3 tablets 
containing highest amount of gelucire in the same time interval (fig 
1). The faster release of GPZ from IPR tablet was attributed to the 
enhancement of solubility of the drug by solid dispersion which 
might have induced solid state transformation of the drug. GPZ did 
not interact with any of the excipients as the characteristic peaks 
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(3251 & 3325/cm for NH stretching, 3060/cm for aromatic CH, 2854 
to 2941/cm for CH stretching, 1649/cm for NH group, 1525 & 
1687/cm for C=O group, 1163 for S=O and 1442 & 686 for CH 
bending respectively) of GPZ [38,39], in the physical mixture and 
IPR tablets appeared at almost the same wave numbers [fig 5]. DSC 
thermograms of GPZ produced a sharp melting endotherm at 216 °C 
corresponding to the melting point of the drug [15]. However the 
melting endotherm was not evident in either the physical mixture or 
the IPR tablets [fig 6]. Moreover the characteristics peaks of GPZ at 
2theta values of 7.49, 11.24, 15.67, 17.10, 18.67 and 21.86were not 
evident in the XRD traces of the physical mixture and IPR tablets [fig 
7]. The results indicate that although the drug was compatible with 
excipients of IPR tablets, the crystalline drug was converted into 
amorphous state. Solid state transformation of drugs during solid 
dispersion process is well documented [40]. 
SR tablets of GPZ were prepared by wet granulation method using 
different ratios of SAL and CG. The compositions of the various 
tablets are shown in [table 3]. All the tablets complied with the 
pharmacopoeial limits with respect to the weight variation, content 
uniformity, friability and thickness. GPZ was compatible with all the 
excipients used in preparation of SR tablets. FTIR study revealed 
that the characteristics peaks of the drugs were present in the 
spectra of both physical mixture and powdered SR tablets [fig 5]. 
The melting endotherm of GPZ at 216 °C was evident in the DSC 
thermograms of the physical mixture and SR tablets [fig 6]. In 
addition XRD diffractograms demonstrated the presence of the 
peaks of the drugs almost at the same 2theta values as found with 
the pure drug [fig 7]. However the intensity of the peaks was found 
to be reduced, which may be due to dilution effect of the drug in the 
formulation [39]. The studies confirmed that GPZ was compatible 
and did not undergo any polymorphic change in the SR tablets.  
The drug release from SR tablets was studied under the dynamic pH 
shift condition where the release study was conducted in acid 
solution of pH 1.2 for the first 2 h and thereafter the pH of the 
medium was increased to pH 6.8 and the results are shown in [fig 2]. 
The release of GPZ was faster from the tablet SR1 prepared with 
highest ratio of SAL/CG. Decrease in the ratio of SAL/CG, as in 
tablets SR2 and SR3, decreased the drug release, and after a certain 
ratio as in SR4, the drug release increased. Variation in drug release 
due to addition of CG in SR layer was further ascertained from the 
values of MDT which was calculated from [Eq. (6)]. One way analysis 
of variance (ANOVA) shows that MDT increased significantly 
[p<0.05] with increase in the amount of CG, and after a certain 
amount of CG, MDT decreased [table 6]. SAL, a biopolymer obtained 
from marine brown algae, is composed of varying proportion of D-
mannuronic acid (M) and L-glucoronic acid (G) residues which are 
arranged in MM or GG blocks interspersed with MG block [41]. It has 
a unique property of forming calcium alginate gel through ionotropic 
gelation with Ca2+ions in simple and mild conditions [42-44]. SR 
tablets consisting of SAL and CG as a source of Ca2+ions were 
prepared by wet granulation method. Ca2+ions which were 
generated from CG in contact with water during the wet massing 
step as well as dissolution study reacted with the acid residues of 
SAL and crosslinked the polymer chain. Crosslinking reduced the 
mobility of the polymer chain and resulted in the formation of a true 
gel layer around the tablet surface in contact with water [45]. 
Increase in the amount of Ca2+ions increased the crosslinking 
density producing higher gel strength and reducing the 
macromolecular mesh size [46, 47]. This resulted in a decrease in 
diffusion and hence the release of GPZ through the gel layer. The 
diffusion coefficient of GPZ through the gel layer formed around the 
SR layer tablet was determined using [Eq. (1)], which was used to 
calculate the diffusion coefficient of drug from spherical matrices 
[21, 48]. Table 6 shows that the values of diffusion coefficient of the 
drug decreased as the amount of CG in the SR tablets was increased, 
and beyond a certain amount, the diffusion coefficient increased. 
The drug release profiles also followed the same trend. Increase in 
drug release at higher level of CG might be due to the presence of 
excess un reacted CG in the tablet, which acted as a channeling agent 
[49]. Among the various SR tablets, SR3 produced prolonged release 
of GPZ extending up to 8 h. But it was not practically feasible to 
compress both SR3 and IPR3 tablet together in 8.7 mm die punch for 
the preparation of bi-layer tablets. So to accommodate both the 
layers in the die punch, the weight of SR3 tablet was reduced to 222 
mg while keeping the ratio of SAL/CG same. The GPZ release profile 
of the resulting SR tablet (SR5) was compared with that of SR3 using 
similarity factor f1 and dissimilarity factor f2. The values of f1 and f2
…… [8] 
 
were calculated respectively from the Eq. 8 and Eq 9 [50, 51] 
 
…… [9] 
Where, P is the number of dissolution time points, and R and T are 
the mean percentage drug released at each time point t from the 
reference and test samples respectively. It was found that the values 
of f1 and f2 were 62.44 and 9.67 respectively. No significant 
difference [p<0.05] was obtained from students t test between f1 
and f2 
Scrutiny of the release profiles of GPZ from IPR and SR tablets 
demonstrated that IPR 3 tablet provided fastest drug release (89% 
of the loaded drug in 30 min), and SR5 tablet produced the most 
extended drug release up to 8 h. Hence, bi-layer tablets BL1 was 
prepared using IPR3 and SR5. The release profiles [fig 4] revealed 
that 37% drug was released quickly in 30 min and thereafter, the 
release extended up to 7 h in a SR manner. In order to further 
prolong the drug release from SR layer, SAL in SR tablet was 
substituted with increasing amount of CMC and the tablets were 
designated as BL2 (SAL: CMC 70:30), BL3 (SAL: CMC 50:50), BL4 
(SAL: CMC 30:70). It was noted substitution of SAL with increasing 
amount of CMC prolonged the drug release. While BL1 released 
100% of the loaded drug in 7 h, BL4 released 70% of the loaded drug 
in 10 h. The release curves clearly exhibited two distinct phases of 
drug release. An initial fast release phase where the slope of the 
curve was higher and a second slow release phase where the slope 
of the release curve was lower [Table 7]. It was further noted that 
IPR in 30 min from all the BL tablets was not the same. This 
indicates that SR layer also contributed to the total drug release. As 
initial release from SR5 was more than that of SR8, the IPR from BL1 
was more than that of BL4. 
values of the two SR tablets. This indicated that the release 
profiles of the tablets SR3 and SR5 did not vary appreciably and 
hence SR5 tablet was selected for the preparation of the bi-layer 
tablets. In order to further prolong the drug release, SR tablet 
designated as SR6, SR7 and SR8 were prepared, wherein, SAL was 
substituted with increasing amount of high viscosity CMC. The 
release profiles [fig 3] revealed that increase in the amount of CMC, 
decreased the drug release. 
 
Table 7: Slope of the immediate release and SR part of the bi-Layer tablets 
Formulation code  Slope 
Fast release part (time 0-10 min) Slow release part (time 30 min-complete release) 
BL1 2.783 0.156 
BL2 2.552 0.136 
BL3 1.741 0.124 
BL4 1.478 0.106 
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The data obtained from in vitro release profiles were fitted in 
various kinetic models as shown in [table 5]. It was observed that 
the IPR layer followed first order release kinetics with correlation 
coefficient of 0.940-0.988, during the initial burst release period of 
the first 30 min where maximum drug was released. Immediate 
release solid dispersion tablets showing first order release kinetics 
is reported in literature [52]. Drug release from SR tablets followed 
zero order release with super case II transport mechanisms. Bi layered 
tablets showed zero order release kinetics after the initial burst 
release, with super case II transport mechanisms. Previous literatures 
of bi-layered tablets with biphasic release pattern also demonstrated 
zero order mechanism after the initial burst release [10].  
CONCLUSION 
In the present study, initially IPR and SR tablets were prepared 
separately to achieve respectively an IPR and slow release of GPZ, an 
antidiabetic drug. Solid state transformation through solid 
dispersion with gelucire enhanced the poor aqueous solubility of the 
drug and induced rapid release from IPR tablets. SR tablets 
produced slow release of the drug by forming a gel around the tablet 
surface and that was further augmented by partial replacement of 
SAL with CMC. The optimized IPR layer was compressed with 
various SR layers to develop bi-layer tablets. Resulting bi-layer 
tablets produced bi-phasic release of the drug at two distinct rates. A 
quick release amounting to 23 to 37% of the drug was obtained in 
30 min, and thereafter, the release was found to prolong at a slower 
rate from 7 h to 10 h depending upon the compositions of the SR 
layers. This study revealed that bi-phasic release of GPZ consisting of 
an initial quick release and subsequent slow release could be 
achieved by formulating bi-layer tablets using the existing tablet 
technology, and such formulation may be able to control 
hyperglycaemia effectively for a longer period of time. 
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